Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer-Reference-Cited by-同舟云学术

Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer

Published:2021-05-01 Issue:5 Volume:157 Page:577
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Thompson Leah L.¹,Krasnow Nira A.¹,Chang Michael S.¹,Yoon Jaewon¹,Li Edward B.¹,Polyakov Nicole J.¹,Molina Gabriel E.¹,Said Jordan T.¹,Huang Kevin¹,Kuchroo Juhi R.¹,Hinton Andrea N.¹,Reynolds Kerry L.²,Chen Steven T.¹

Affiliation:

1. Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston

2. Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston

Publisher

American Medical Association (AMA)

Subject

Dermatology

Link

https://jamanetwork.com/journals/jamadermatology/articlepdf/2777660/jamadermatology_thompson_2021_br_210003_1620146135.08245.pdf

Reference15 articles.

1. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.;Coleman;J Am Acad Dermatol,2019

2. Immune checkpoint inhibitor–related dermatologic adverse events.;Geisler;J Am Acad Dermatol,2020

3. Dermatologic reactions to immune checkpoint inhibitors.;Sibaud;Am J Clin Dermatol,2018

5. Association of immune-related adverse events with nivolumab efficacy in non–small-cell lung cancer.;Haratani;JAMA Oncol,2018

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral Antibiotics and Risk of Serious Cutaneous Adverse Drug Reactions;JAMA;2024-09-03

2. Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study;The Lancet Oncology;2024-08

3. Sicca syndrome/Sjögren’s disease associated with cancer immunotherapy: a narrative review on clinical presentation, biomarkers, and management;Expert Review of Clinical Immunology;2024-06-25

4. De novo autoimmune connective tissue disease and mortality in patients treated with anti-programmed death receptor-1 and anti-programmed death-ligand 1 therapy: a population-level cohort study;British Journal of Dermatology;2024-04-28

5. Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways;Clinical Cancer Research;2024-04-23